New client programme to be supported from OXB’s FDA-approved, commercial scale viral vector manufacturing facility in Durham, North Carolina, ...
Progression to full ownership aligns with global strategy and supports long-term growth in the viral vector manufacturing market Oxford, UK – 23 June 2025: OXB (LSE: OXB) (“the Company”), a global ...
Oxford, UK – 2 June 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, will today host a Capital Markets Event for equity research analysts and institutional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results